z-logo
open-access-imgOpen Access
Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma
Author(s) -
Beatrice Razzo,
Nils Ludwig,
ChangSook Hong,
Prateek Sharma,
Kellsye P. Fabian,
Ronald J. Fecek,
Walter J. Storkus,
Theresa L. Whiteside
Publication year - 2019
Publication title -
carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.688
H-Index - 204
eISSN - 1460-2180
pISSN - 0143-3334
DOI - 10.1093/carcin/bgz124
Subject(s) - microvesicles , cancer research , immune system , carcinogenesis , tumor progression , cd8 , cancer , tumor microenvironment , carcinogen , biology , pathology , medicine , immunology , microrna , biochemistry , genetics , gene
Circulating tumor-derived exosomes (TEX) interact with a variety of cells in cancer-bearing hosts, leading to cellular reprogramming which promotes disease progression. To study TEX effects on the development of solid tumors, immunosuppressive exosomes carrying PD-L1 and FasL were isolated from supernatants of murine or human HNSCC cell lines. TEX were delivered (IV) to immunocompetent C57BL/6 mice bearing premalignant oral/esophageal lesions induced by the carcinogen, 4-nitroquinoline 1-oxide (4NQO). Progression of the premalignant oropharyngeal lesions to malignant tumors was monitored. A single TEX injection increased the number of developing tumors (6.2 versus 3.2 in control mice injected with phosphate-buffered saline; P < 0.0002) and overall tumor burden per mouse (P < 0.037). The numbers of CD4+ and CD8+ T lymphocytes infiltrating the developing tumors were coordinately reduced (P < 0.01) in mice injected with SCCVII-derived TEX relative to controls. Notably, TEX isolated from mouse or human tumors had similar effects on tumor development and immune cells. A single IV injection of TEX was sufficient to condition mice harboring premalignant OSCC lesions for accelerated tumor progression in concert with reduced immune cell migration to the tumor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here